Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2017
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- 06 Nov 2015 Results published in the Annals of Allergy, Asthma and Immunology
- 28 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.